Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

Brian Lian

Michael Dinerman

Viking Therapeutics, Inc.

Summit Therapeutics is a biopharmaceutical oncology company focused on the discovery, development, and commercialization of medicinal therapies intended to improve quality of life and resolve serious unmet medical needs, self-described.

Summit Therapeutics

Pharma Now is a monthly B2B magazine that covers trends, technological innovations, and insights in the pharmaceutical and biopharmaceutical sectors. It provides industry news and updates, interviews with leaders, market insights, and regulatory updates.

Pharma Now

Viking Therapeutics, Inc. (Nasdaq:VKTX) is a clinical-stage company focused on the development of first-in-class or best-in-class therapies for metabolic and endocrine disorders. Our most advanced candidate is a non-steroidal selective androgen receptor modulator (SARM) currently in Phase 2 trial for the treatment recovery from hip fracture surgery. Our thyroid receptor beta (TRb) agonist platform, also in Phase 2, is being developed for lipid disorders such as hypercholesterolemia and fatty liver diseases such as non-alcoholic steatohepatitis (NASH) as well as for rare diseases of glycogen storage disease (GSD 1a) and X-linked adrenoleukodystrophy, or X-ALD. See more at http://www.vikingtherapeutics.com



Metric
Company Name	Viking Therapeutics, Inc.	Summit Therapeutics	Pharma Now
Symbol	VKTX
MSH ID	COM:VIKINGTHERAPEUTICS	COM:SUMMITTHERAPEUTICS	LIVE:PHARMANOW
Market	STOCKS	PRIVATE	PRIVATE
Sector	Healthcare	Healthcare & Health Services	Consumer Services
Industry	Biotechnology	Biotechnology	Pharmaceuticals
Country	US	US	IN
Stage	Post-IPO Equity	Post-IPO Equity
Employee Count	28
Website	vikingtherapeutics.com	summittherapeutics.com	pharmanow.live
LinkedIn	viking-therapeutics		pharma-now
Founders

Metric
Market Cap	6.39B
Enterprise Value
Monthly Web Traffic	20.52K	1.36K
Web Traffic Growth	2.50	-0.08
Valuation
Raised Capital	632.50M	235M

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:VIKINGTHERAPEUTICS

Viking Therapeutics, Inc.

Last Close

51.63

22/11 21:00

Market Cap

6.39B

Beta: -

Volume Today

2.63M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue